Treatment of Niemann--pick type C disease by histone deacetylase inhibitors.
about
Diagnostic workup and management of patients with suspected Niemann-Pick type C diseasePluronic based β-cyclodextrin polyrotaxanes for treatment of Niemann-Pick Type C disease.Niemann-Pick C disease and mobilization of lysosomal cholesterol by cyclodextrinA potent HDAC inhibitor, 1-alaninechlamydocin, from a Tolypocladium sp. induces G2/M cell cycle arrest and apoptosis in MIA PaCa-2 cells.Epigenetic regulation of cholesterol homeostasis.Mutant glucocerebrosidase in Gaucher disease recruits Hsp27 to the Hsp90 chaperone complex for proteasomal degradationComputational design of a time-dependent histone deacetylase 2 selective inhibitor.A novel, highly sensitive and specific biomarker for Niemann-Pick type C1 disease.Quantitative Proteomics of Human Fibroblasts with I1061T Mutation in Niemann-Pick C1 (NPC1) Protein Provides Insights into the Disease Pathogenesis.Neuronal gene repression in Niemann-Pick type C models is mediated by the c-Abl/HDAC2 signaling pathway.Identification of novel bile acids as biomarkers for the early diagnosis of Niemann-Pick C disease.Treatment of lysosomal storage disorders: successes and challenges.Histone deacetylase inhibitors correct the cholesterol storage defect in most Niemann-Pick C1 mutant cells.Role of STARD4 and NPC1 in intracellular sterol transport.Reduction of TMEM97 increases NPC1 protein levels and restores cholesterol trafficking in Niemann-pick type C1 disease cells.PEG-lipid micelles enable cholesterol efflux in Niemann-Pick Type C1 disease-based lysosomal storage disorder.Looking above but not beyond the genome for therapeutics in neurology and psychiatry: epigenetic proteins and RNAs find a new focus.Cyclodextrin Alters GABAergic Input to CA1 Pyramidal Cells in Wild-Type But Not in NPC1-Deficient Mice.Generation of patient specific human neural stem cells from Niemann-Pick disease type C patient-derived fibroblasts.Recent neuroimaging, neurophysiological, and neuropathological advances for the understanding of NPC.Linear Cyclodextrin Polymer Prodrugs as Novel Therapeutics for Niemann-Pick Type C1 Disorder.
P2860
Q26748586-24D0AA89-CA79-415B-A35E-41B1425CF53AQ33612118-1106F70D-3AD3-4D70-AED7-070491B4257CQ33945068-356BA5D9-CA6B-4A69-B74C-67CDF46AF22AQ33960767-DAE0DFDD-2A06-4D67-B8F6-DF888BDC4C75Q34238886-6753DC0F-8DD5-4AEF-B437-4135847F7F9EQ35037986-FC2E737A-847A-479E-87B4-C253B8994BB6Q35213063-46674AC4-A9DB-40E8-BA4F-E044488E2E26Q35775542-0C5C0303-6946-4E21-AF7A-D052CC9DF9B3Q36103923-AFD1468B-D06D-4BDA-8325-F8EB7B058543Q37238365-5984C563-20F5-4036-8A23-41F6D2AD90A8Q37384927-02040C95-935F-4C31-83E6-3BAB31B529FBQ38211269-661C3379-538A-47FC-BD18-E990D8EFAAA2Q38716617-755389D6-8E50-4876-926F-E6D5C442EAE1Q38897940-3EAF096F-550C-45B7-B125-73545EB4B924Q39732986-B76DB59B-F508-4F46-ADAE-4EB8F54E663FQ40971346-9555B98E-9A74-492B-8C5D-751C5386FD35Q42937645-2B7934AE-C334-4E4E-AD83-30CA6787F173Q43014028-435A3CBB-97A3-48DE-8349-ABC19D77A247Q47140917-1EC3D728-8D6A-43FE-9140-ECBBEB7612BBQ52670912-F0F79F9B-5A59-4457-996A-7BAE8BEC1491Q55498018-1566BA26-C38A-4476-8538-B64833CF6356
P2860
Treatment of Niemann--pick type C disease by histone deacetylase inhibitors.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Treatment of Niemann--pick type C disease by histone deacetylase inhibitors.
@en
type
label
Treatment of Niemann--pick type C disease by histone deacetylase inhibitors.
@en
prefLabel
Treatment of Niemann--pick type C disease by histone deacetylase inhibitors.
@en
P2093
P2860
P1433
P1476
Treatment of Niemann--pick type C disease by histone deacetylase inhibitors
@en
P2093
Norbert L Wiech
Olaf Wiest
Paul Helquist
P2860
P2888
P304
P356
10.1007/S13311-013-0217-2
P577
2013-10-01T00:00:00Z